19:48 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

Roche's Ventana approved as companion diagnostic for Novartis' Zykadia

In June, Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients eligible for Zykadia ceritinib (LDK378) from...
23:17 , Jul 7, 2017 |  BC Extra  |  Financial News

Qiagen Suzhou raises RMB175M in series A

Molecular diagnostics company Qiagen Suzhou Translational Medicine Co. Ltd. (Suzhou, China) raised RMB175 million ($25.8 million) in a series A round led by Qiming Venture Partners. Quan Capital, BoYueZhiYuan Capital and Shanghai Angel Medical Instrument...
22:07 , Mar 17, 2017 |  BioCentury  |  Tools & Techniques

Calibrating PD-L1

Flagship Biosciences Inc. ’s Computational Tissue Analysis platform won’t provide a common cutoff point across the five major assays used to measure PD-L1 expression. But it could calibrate the output so that results from one...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Ventana ALK regulatory update

FDA approved the Ventana ALK (D5F3) CDx Assay from Roche’s Ventana Medical Systems Inc. unit for the qualitative detection of anaplastic lymphoma kinase (ALK) protein in non-small cell lung cancer (NSCLC) sample and as an...
08:00 , Feb 2, 2015 |  BioCentury  |  Product Development

Remote controlled CARs

A three-way deal between Intrexon Corp. , Ziopharm Oncology Inc. and the University of Texas MD Anderson Cancer Center aims to tackle at least two of the major challenges for CAR and T cell-based immunotherapies...
02:22 , Dec 19, 2014 |  BC Extra  |  Top Story

Juno prices IPO; Bellicum soars

Cancer immunotherapy plays Juno Therapeutics Inc. (NASDAQ:JUNO) and Bellicum Pharmaceuticals Inc. (NASDAQ:BCLM) priced their upsized IPOs, with Bellicum gaining in first-day trading Thursday. Juno priced above its proposed range at $24 and raised $264.6 million...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Ariad, Bellicum deal

Ariad and Bellicum amended a 2006 deal granting Bellicum rights to use Ariad's cell-signaling technology. Under the amendment, Bellicum will pay Ariad $50 million in exchange for an exclusive, worldwide license to use the technology...
02:24 , Oct 7, 2014 |  BC Extra  |  Company News

Bellicum pays Ariad for room to run

After raising $55 million in August, Bellicum Pharmaceuticals Inc. (Houston, Texas) on Monday committed to pay $50 million to Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) for exclusive worldwide rights to use the latter's cell-signaling technology in human...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Ventana ALK regulatory update

Roche's Ventana Medical Systems Inc. tissue diagnostic unit said China's State Food and Drug Administration (CFDA) approved its Ventana ALK (D5F3) Rabbit Monoclonal Primary Antibody assay to identify anaplastic lymphoma kinase (ALK) protein expression in...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Cell Signaling Technology, Cepheid deal

Cell Signaling granted Cepheid a non-exclusive, worldwide license to Cell Signaling's patents covering the detection of anaplastic lymphoma kinase (ALK) gene rearrangements for the field of PCR diagnostic testing. The patents include method claims that...